Jahan Rahman

Jahan Rahman

Auto-generated profile, based on publicly available information

Jahan Rahman

Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2022 in Nature
Verified
Journal Article
Closed access
PDF file
MLMateusz Legut
Mateusz Legut
ZGZoran Gajic
Zoran Gajic
MGMaria Guarino
Maria Guarino
ZDZharko Daniloski
Zharko Daniloski
JRJahan A. Rahman
Jahan A. Rahman
NSNeville E. Sanjana
Neville E. Sanjana

17 June 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SHSteven M. Horwitz
Steven M. Horwitz
ANAjit J. Nirmal
Ajit J. Nirmal
JRJahan Rahman
Jahan Rahman
RXRan Xu
Ran Xu
EDEsther Drill
Esther Drill
SVSantosha Vardhana
Santosha Vardhana

30 October 2021 in iScience
Verified
Journal Article
Open access
JMJohn A. Morris
John A. Morris
JRJahan A. Rahman
Jahan A. Rahman
XGXinyi Guo
Xinyi Guo
NSNeville E. Sanjana
Neville E. Sanjana
Prime editors (PEs) are clustered regularly interspaced short palindromic repeats (CRISPR)-based genome engineering tools that can introduce precise base-pair edits. We developed an automated pipeline to correct (therapeutic editing) or introduce (disease modeling) human pathogenic variants from ClinVar that optimizes the design of several RNA constructs required for prime editing and avoids predicted off-targets in the human genome. However, using optimal PE design criteria, we find that only a small fraction of these pathogenic variants can be targeted. Through the use of alternative Cas9 enzymes and extended templates, we increase the number of targetable pathogenic variants from 32,000 to 56,000 variants and make these pre-designed PE constructs accessible through a web-based portal (http://primeedit.nygenome.org). Given the tremendous potential for therapeutic gene editing, we also assessed the possibility of developing universal PE constructs, finding that common genetic variants impact only a small minority of designed PEs.

3 June 2024 in Research Square
Verified
Preprint
Open access
PDF file
JOJuan Osorio
Juan Osorio
DKDavid Knorr
David Knorr
PWPolina Weitzenfeld
Polina Weitzenfeld
NYNing Yao
Ning Yao
MBMaria Baez
Maria Baez
JRJeffrey Ravetch
Jeffrey Ravetch
While CD40 agonism is an attractive approach for activating antigen-presenting cells and initiating antitumor responses, previous attempts have encountered limited clinical efficacy coupled with toxicity. We previously demonstrated that interactions between the antibody Fc domain and the inhibitory receptor FcγRIIB are critical for enhanced antitumor activity. Here, we present the results of a phase 1 study on intratumoral administration of an anti-CD40 agonistic antibody (2141-V11) Fc-engineered to enhance FcγRIIB binding. Primary endpoints included safety, maximum tolerated dose (MTD), and recommended phase 2 dose. Secondary objectives included preliminary clinical activity and correlative studies from biospecimens. 2141-V11 was well-tolerated without dose-limiting toxicities and MTD was not reached. In ten evaluable patients with metastatic cancer, the overall response rate was 20%, with complete responses in two patients (melanoma and breast carcinoma) and stable disease in six patients. 2141-V11 induced tumor regression in injected and non-injected lesions, with increased leukocyte infiltration and tertiary lymphoid structures (TLS) formation in post-treatment biopsies. In a humanized mouse model for CD40 and FcγRs, 2141-V11 induced TLS formation in mice bearing orthotopic breast carcinoma, correlating with local and abscopal antitumor effects, systemic immune activation, and immune memory. These findings support the safety and efficacy of 2141-V11, warranting phase 2 studies and suggesting a unique mechanism of action for this Fc-enhanced immunotherapy (NCT04059588).

9 May 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
JMJohn A. Morris
John A. Morris
JRJahan A. Rahman
Jahan A. Rahman
XGXinyi Guo
Xinyi Guo
NSNeville E. Sanjana
Neville E. Sanjana
Prime editors (PEs) are CRISPR-based genome engineering tools that can introduce precise base-pair edits at specific locations in the genome. These programmable gene editors have been predicted to repair 89% of known human pathogenic variants in the ClinVar database, although these PE constructs do not presently exist. Towards this end, we developed an automated pipeline to correct (therapeutic editing) or introduce (disease modeling) human pathogenic variants that optimizes the design of several RNA constructs required for prime editing and avoids predicted off-targets in the human genome. However, using optimal PE design criteria, we find that only a small fraction of these pathogenic variants can be targeted. Through the use of alternative Cas9 enzymes and extended templates, we increase the number of targetable pathogenic variants to >50,000 variants and make these pre-designed PE constructs accessible through a web-based portal ( http://primeedit.nygenome.org ). Given the tremendous potential for therapeutic gene editing, we also assessed the possibility of developing universal PE constructs. By examining the overlap of different PE components with common human genetic variants in dbSNP, we find that common variants affect only a small minority of designed PEs.

12 August 2025 in Cancer Discovery
Verified
Journal Article
Closed access
PZPu Zhang
Pu Zhang
ZCZhendong Cao
Zhendong Cao
XPXiangyu Pan
Xiangyu Pan
YLYuqiao Liu
Yuqiao Liu
CCCynthia Castro
Cynthia Castro
JSJunwei Shi
Junwei Shi
GTPase-activating proteins (GAP) and guanine nucleotide exchange factors (GEF) play key roles in cancer development, but their large number and potential redundancy have limited systematic evaluation. In this study, we perform unbiased genetic screens to identify GAPs and GEFs with cancer- and lineage-specific requirements, as well as dual perturbation screens to dissect functionally relevant interactors of GAPs and GEFs. Application to primary specimens from patients with acute myeloid leukemia uncovers the GAP ARHGAP45 as a targetable dependency shared across cancers of hematopoietic origin while being dispensable in normal hematopoiesis. We demonstrate that targeting ARHGAP45-expressing cells can be achieved through T-cell receptor chimeric antigen receptor T cells directed at an ARHGAP45-encoded minor histocompatibility antigen and that pharmacologic targeting of CDC42 required upon ARHGAP45 depletion augments ARHGAP45-directed cell therapies. These studies provide a resource for probing oncogenic and druggable regulators of GTPases and strategies to target a GAP that represents a shared dependency across blood cancers. Significance: In this study, we systematically interrogated GAPs and GEFs in cancer and identified the GAP ARHGAP45 as a dependency shared across blood cancers while dispensable in normal hematopoiesis. Targeting ARHGAP45-expressing cells is achievable via T-cell receptor chimeric antigen receptor T cells directed at an ARHGAP45-derived antigen and small-molecule inhibition of GTPases required upon ARHGAP45 loss.